Banking

Teva Stock Dips As The Sales Downfall Continues For Its Biggest Product

Early Wednesday, Teva Pharmaceutical (TEVA) reported adjusted earnings of 59 cents per share on $3.89 billion in third-quarter revenue. In response, Teva stock slipped.




X



On average, analysts polled by FactSet expected Teva to earn 65 cents per share on $4.07 billion in sales. But sales of Teva’s biggest single product, the multiple sclerosis drug Copaxone, continued to fall amid generic competition.

In the year-earlier period, Teva earnings were 58 cents per share and the generic drugs maker reported $3.98 billion in sales.

For the year, Teva guided to earnings of $2.50-$2.70 per share and $16 billion to $16.4 billion in sales. Teva stock analysts called for adjusted profit of $2.62 a share and $16.35 billion in sales.

In premarket trading on today’s stock market today, Teva stock fell 1.7% near 9.20. Shares are now well below their 200-day moving average, according to MarketSmith.com. On Tuesday, they dropped down to their 50-day line.

More to follow.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.

YOU MAY ALSO LIKE:

Novartis Mulls Selling Underperforming Unit As Sales Decline Continues

The Eli Lilly-Biogen Clash In Alzheimer’s Begins — How Will It Play Out?

See IBD Stock Lists & Get Pass/Fail Ratings For All Your Stocks With IBD Digital

Learn How To Time The Market With IBD’s ETF Market Strategy

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks


Most Related Links :
Business News Governmental News Finance News

Source link

Back to top button